AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer

December 18, 2019 GMT
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer

SAN DIEGO--(BUSINESS WIRE)--Dec 18, 2019--

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191218005733/en/

Stephanie Fagan, Senior Vice President, Corporate Affairs and Chief Communications Officer (Photo: Business Wire)

“Stephanie brings extensive experience working with leading healthcare companies and brands, and her commitment to patients, customer and community engagement will strengthen the ACADIA mission of improving the lives of people who struggle with unmet needs in neurological disorders,” said Ms. Ridloff. “I’m delighted to welcome Stephanie to ACADIA as her strong track record of developing the communications function with high-performing teams that engage multiple stakeholders will advance our business strategies.”

“As ACADIA continues to expand its research, development and commercial efforts, I look forward to working with the team and engaging with the communities we serve to keep ACADIA at the forefront of developing and delivering new therapies for patients and their families with central nervous system disorders,” said Ms. Fagan.

Ms. Fagan joins ACADIA from bluebird bio, Inc. where she was Senior Vice President, Corporate Communications and built the first communications function as the company transitioned from a clinical stage to commercial stage company. Prior to bluebird, Ms. Fagan led the corporate affairs functions at Alexion, Shire, and West Health and has experience overseeing corporate, financial, product, and internal communications, as well as corporate social responsibility, patient advocacy, and government affairs. Over the course of her career, Ms. Fagan has served in positions of increasing influence and impact in the healthcare industry, including roles at Johnson & Johnson, Allergan, Pharmacia, Inc. (now Pfizer), and Boston Scientific Corporation.

Ms. Fagan earned a Master’s degree in Communications from Boston University and a Bachelor’s degree in English from Wheaton College. She is a member of the Arthur Page Society and The Seminar.

About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2018 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191218005733/en/

CONTACT: Media Contact:

ACADIA Pharmaceuticals Inc.

Stephanie Fagan

(858) 212-0534

media@acadia-pharm.comInvestor Contact:

ACADIA Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PUBLIC RELATIONS/INVESTOR RELATIONS HEALTH COMMUNICATIONS PHARMACEUTICAL

SOURCE: ACADIA Pharmaceuticals Inc.

Copyright Business Wire 2019.

PUB: 12/18/2019 04:05 PM/DISC: 12/18/2019 04:05 PM

http://www.businesswire.com/news/home/20191218005733/en